Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) FCF Margin (2016 - 2025)

Wave Life Sciences' FCF Margin history spans 11 years, with the latest figure at 532.45% for Q2 2025.

  • For Q2 2025, FCF Margin fell 39270.0% year-over-year to 532.45%; the TTM value through Dec 2025 reached 1052.99%, down 98741.0%, while the annual FY2025 figure was 440.5%, 30018.0% down from the prior year.
  • FCF Margin reached 532.45% in Q2 2025 per WVE's latest filing, up from 688.87% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 657.69% in Q1 2023 to a low of 9158.95% in Q3 2022.
  • Average FCF Margin over 5 years is 1312.88%, with a median of 154.31% recorded in 2023.
  • Peak YoY movement for FCF Margin: plummeted -908130bps in 2022, then soared 908853bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 9.05% in 2021, then tumbled by -358bps to 41.43% in 2022, then skyrocketed by 37bps to 26.21% in 2023, then grew by 16bps to 21.92% in 2024, then crashed by -2329bps to 532.45% in 2025.
  • Per Business Quant, the three most recent readings for WVE's FCF Margin are 532.45% (Q2 2025), 688.87% (Q1 2025), and 21.92% (Q4 2024).